Combination Vaccines
Multi-antigen vaccines combining protection against two or more diseases in a single product
This page catalogs 34 combination vaccine products spanning currently US-licensed DTaP, Tdap, MMR, MMRV, and hexavalent formulations, European equivalents, WHO-prequalified pentavalent products, and discontinued predecessors. Combination vaccines reduce the number of injections required, improving immunization compliance and coverage. This is the largest single category in the Vaccine Catalog.
Last updated: April 2026.
Combination Vaccine Catalog
| Trade Name | Generic Designation | Manufacturer | Vaccine Type | Regulatory Status & Year | Key Notes |
|---|---|---|---|---|---|
| Daptacel | DTaP (diphtheria, tetanus, acellular pertussis) | Sanofi Pasteur | Toxoid + acellular | FDA Licensed, 2002 | Pediatric DTaP |
| Infanrix | DTaP | GSK | Toxoid + acellular | FDA Licensed, 1997 | Pediatric DTaP |
| Adacel | Tdap (tetanus, diphtheria, acellular pertussis) | Sanofi Pasteur | Toxoid + acellular | FDA Licensed, 2005 | Adolescent/adult booster |
| Boostrix | Tdap | GSK | Toxoid + acellular | FDA Licensed, 2005 | Adolescent/adult booster; maternal use |
| Tenivac | Td (tetanus + diphtheria adult) | Sanofi Pasteur | Toxoid | FDA Licensed | Adult Td booster |
| TDVAX | Td (tetanus + diphtheria adult) | MassBiologics | Toxoid | FDA Licensed | Adult Td |
| M-M-R II | Measles, mumps, rubella | Merck | Live-attenuated viral | FDA Licensed, 1978 | Standard MMR |
| Priorix | Measles, mumps, rubella | GSK | Live-attenuated viral | FDA Licensed, 2022 | Second US MMR |
| ProQuad | MMRV (measles, mumps, rubella, varicella) | Merck | Live-attenuated viral | FDA Licensed, 2005 | 4-in-1 MMRV |
| Pediarix | DTaP-HepB-IPV | GSK | Combination | FDA Licensed, 2002 | 5-in-1 pediatric |
| Pentacel | DTaP-IPV/Hib | Sanofi Pasteur | Combination | FDA Licensed, 2008 | 5-in-1 with Hib |
| Kinrix | DTaP-IPV | GSK | Combination | FDA Licensed, 2008 | 4-in-1 booster |
| Quadracel | DTaP-IPV | Sanofi Pasteur | Combination | FDA Licensed, 2015 | 4-in-1 booster |
| Vaxelis | DTaP-IPV-Hib-HepB | MSP Vaccine Co (Merck/Sanofi) | Combination | FDA Licensed, 2018 | 6-in-1 hexavalent |
| Infanrix Hexa | DTaP-IPV-Hib-HepB | GSK | Combination | EMA Authorized | GSK hexavalent; not US-licensed |
| Hexaxim / Hexyon | DTaP-IPV-Hib-HepB | Sanofi Pasteur | Combination | EMA Authorized | Sanofi hexavalent; not US-licensed |
| Twinrix | Hepatitis A + Hepatitis B | GSK | Inactivated + Recombinant | FDA Licensed, 2001 | Combination Hep A/B adult |
| Penbraya | MenABCWY | Pfizer | Conjugate + recombinant | FDA Licensed, 2023 | First pentavalent meningococcal |
| Penmenvy | MenABCWY | Sanofi | Conjugate + recombinant | FDA Licensed, 2025 | Second pentavalent meningococcal |
| Trihibit | DTaP/Hib | Sanofi Pasteur | Combination | FDA Licensed; Discontinued | Discontinued combination |
| Tri-Immunol | DTP (whole-cell pertussis) | Wyeth-Lederle | Toxoid + killed bacterial | FDA Licensed; Discontinued | Whole-cell DTP; replaced by DTaP |
| Tripedia | DTaP | Sanofi Pasteur (Aventis) | Toxoid + acellular | FDA Licensed, 1992; Discontinued | Early acellular pertussis |
| ACEL-IMUNE | DTaP | Wyeth-Lederle | Toxoid + acellular | FDA Licensed; Discontinued | Early DTaP |
| Certiva | DTaP | North American Vaccine | Toxoid + acellular | FDA Licensed; Discontinued | Single pertussis antigen DTaP |
| Biavax | Rubella-Mumps vaccine | Merck | Live-attenuated viral | FDA Licensed; Discontinued | MR combination; replaced by MMR |
| Pluserix | MMR vaccine | SKB/GSK | Live-attenuated viral | Licensed (non-US); Withdrawn | Urabe mumps strain; withdrawn after meningitis signal |
| Pediace | DTaP-IPV-Hib | Sanofi Pasteur | Combination | Licensed (non-US) | Canadian/EU 5-in-1 |
| Quinvaxem | DTP-HepB-Hib pentavalent | Novartis/Biological E | Whole-cell combination | WHO Prequalified; Discontinued | WHO-prequalified pentavalent for GAVI |
| Repevax | Tdap-IPV | Sanofi Pasteur | Combination | Licensed (EU) | European Tdap-IPV booster |
| Tri-Solgen | DTP (whole-cell) | Wyeth | Toxoid + killed bacterial | Discontinued | Historical whole-cell DTP |
| Tri-Immunol (alt) | DTP (whole-cell) | Lederle | Toxoid + killed bacterial | Discontinued | Lederle whole-cell DTP |
| Trivax | DTP (whole-cell) | Wellcome | Toxoid + killed bacterial | Discontinued | UK whole-cell DTP |
| Refortrix | Tdap | GSK | Toxoid + acellular | Licensed (non-US) | European Tdap booster |
| Revaxis | Td-IPV (tetanus-diphtheria-polio) | Sanofi Pasteur | Toxoid + inactivated | Licensed (EU) | European Td-IPV adult booster |
Sources
Regulatory data sourced from FDA CBER Vaccines Licensed for Use in the United States (March 2026), EMA Medicines database, and WHO Prequalified Vaccines list. Historical context informed by Khan, Shaz, The Ultimate Vaccine Timeline.